Effect of Eugenia jambolana (Maghz-e-jamun,jamun guthli)in Prediabetics

Clinical evaluation of Eugenia jambolana (Maghz-e-jamun)in Prediabetics

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2017/07/009063

Enrollment

Registered

2017-07-17

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Intervention1: Eugenia jambulana: powder form in capsules. each capsules containing 0.75g powder. 3 capsules will be given orally twice a day for 12 weeks. Control Intervention1: Placebo: 0.75 g in ca

Eligibility

Inclusion criteria

Inclusion criteria: 1. Patients having Fasting Blood Sugar range 100-125mg/dl or 2. 2hr plasma glucose level range 140-199mg/dl. (after 75g glucose load on OGTT) or 3. HbA1C in 5.7%-6.4% range. 4. Patients willing to sign the written informed consent.

Exclusion criteria

Exclusion criteria: 1. Patients having FBS below 100mg/dl or above 125mg/dl. 2. Pre-diabetics suffering from any severe complications. 3. Patients with deranged kidney and liver profiles. 4. Patients with any chronic diseases. 5. Pregnant & lactating mothers. 6. Patients who fail to give consent. 7. Patients who fail to follow up. 8. Mentally retarded persons.

Design outcomes

Primary

Measure	Time frame
Blood Sugar Fasting 2 hr plasma glucose level (after 75g glucose load on OGTT) HbA1C Lipid Profile Serum Insulin HOMA-IR Timepoint: 28th day , 56thday and 84th day	—

Secondary

Measure	Time frame
Serum Insulin HOMA-IR Lipid ProfileTimepoint: 28th day , 56thday and 84th day	—

Countries

India

Contacts

Public ContactDr Shagufta Parveen

Jamia Hamdard

asim_jhamdard@yahoo.in

Outcome results